Shared immune-inflammatory gene networks and drug prediction in polycystic ovary syndrome and type 2 diabetes mellitus: a bioinformatics and experimental validation study - Scorecard - MDSpire
Advertisement
Shared immune-inflammatory gene networks and drug prediction in polycystic ovary syndrome and type 2 diabetes mellitus: a bioinformatics and experimental validation study
Clinical Scorecard: Identification of Common Immune-Inflammatory Gene Pathways and Drug Repurposing in Polycystic Ovary Syndrome and Type 2 Diabetes Mellitus: A Bioinformatics and Experimental Study
At a Glance
Category
Detail
Condition
Polycystic Ovary Syndrome (PCOS) and Type 2 Diabetes Mellitus (T2DM)
Key Mechanisms
Shared immune regulation and inflammatory processes involving hub genes related to neutrophil degranulation, dendritic cell chemotaxis, follicular B cell differentiation, and integrin complexes
Target Population
Reproductive-aged women with PCOS and patients with T2DM, including adolescents
Care Setting
Clinical and research settings focusing on metabolic and endocrine disorders
Key Highlights
PCOS and T2DM exhibit a bidirectional comorbidity linked by shared immune-inflammatory gene pathways.
Nine hub genes (ITGAM, ITGB2, SPI1, C1QB, CCR5, C3AR1, LY86, AIF1, IRF8) were identified as central to the shared pathogenesis.
Potential therapeutic drugs targeting these hub genes include maraviroc, cenicriviroc, PF-04634817, butein, dimethyl sulfoxide, and rovelizumab.
Guideline-Based Recommendations
Diagnosis
Consider screening for T2DM in women diagnosed with PCOS, especially those with hyperandrogenism and insulin resistance.
Evaluate PCOS symptoms in adolescent girls diagnosed with T2DM due to increased prevalence.
Management
Target immune-inflammatory pathways identified by hub genes for novel therapeutic strategies.
Explore repurposing drugs such as CCR5 antagonists (maraviroc, cenicriviroc, PF-04634817) and agents targeting ITGAM and ITGB2 for treatment.
Monitoring & Follow-up
Monitor metabolic parameters including insulin sensitivity and glucose tolerance in PCOS patients.
Assess inflammatory markers and immune gene expression profiles where feasible to understand disease progression.
Risks
Recognize increased risk of T2DM in PCOS patients, particularly those with hyperandrogenic phenotypes.
Acknowledge the economic and health burden associated with the comorbidity of PCOS and T2DM.
Patient & Prescribing Data
Women of reproductive age with PCOS and patients with T2DM, including adolescents
Drugs targeting CCR5 and integrin-related pathways show potential; however, clinical validation is required before routine use.
Clinical Best Practices
Integrate metabolic and reproductive evaluations in patients presenting with either PCOS or T2DM.
Utilize bioinformatics and gene expression profiling to identify patient-specific therapeutic targets.
Consider the role of immune and inflammatory mechanisms when developing treatment plans for PCOS and T2DM comorbidity.
